| Subtyp | Rezeptorgene exprimiert | Proliferationsgene exprimiert | Her2neu überexprimiert | Bemerkungen |
| Luminal A | ER+ oder PR+ | G1-2 Ki67 < 14% | Her2- | keine Proliferationsgene, Östrogenrezeptorgene |
| Luminal B | ER+ oder PR- | G3, Ki76 > 14% | Her2- | Proliferationsgene, Östrogenrezeptorgene |
| Luminal Her2 | ER+ oder PR+ | - | Her2+, | |
| Her2 | ER- PR- | - | Her2+ | |
| Basal- like | ER- PR- | - | Her- | tripple negative breast cancer, TNBC |
| Subtyp | Anteil | < 50 Jahre | nicht duktal (lobulär o.a.) | Grading 3 |
| Luminal A | 60.3 | 27.1 % | 17.6% | 0% |
| Luminal B | 14.7 | 32.7% | 4.1% | 100% |
| Luminal Her2 | 11.1 | 35.3% | 3.2% | 63.5% |
| Her2 | 5.3 | 34.3% | 1.0% | 83.5% |
| Basal- like | 8.6 | 28.5% | 2.9% | 78.9% |
| Subtyp | OS / Monate | PFS-1 / Monate | PPS-1 / Monate |
| Luminal A | 45,3 | 15,1 | 24 |
| Luminal B | 29,7 | 9,3 | 18,9 |
| Her2 pos. | 43,5 | 10 | 19 |
| Triple negativ | 10,2 | 3,9 | 6,1 |
PFS-1: Progressionsfreies Überleben nach first-line-Therapie
PPS-1: Postprogression Überleben nach first-line-Therapie
Teil von
Gene expression pattern of breast carcinomas distinguish tumor subclasses with clinical implications.
Proc Natl Acad Sci USA 98(2001):10869-74
2.) Perou CM, et al.:
Molecular portraits of human breast tumours.
Nature 406(2000):747-752.
3.) Truong PT, et al.:
Is Biological Subtype Prognostic of Locoregional Recurrence Risk in Women With pT1-2N0 Breast Cancer Treated With Mastectomy?
Int J Radiation Oncol Biol Phys 88(2014): 57-64
4.) Bonotto M, et al.:
Measures of outcome in metastatic breast cancer: insights from a real-world scenario.
The Oncologist 19(2014):608-615
